» Articles » PMID: 26534909

Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity

Overview
Journal Cereb Cortex
Specialty Neurology
Date 2015 Nov 5
PMID 26534909
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Abnormal accumulation of aggregated α-synuclein (aSyn) is a hallmark of sporadic and familial Parkinson's disease (PD) and related synucleinopathies. Recent studies suggest a neuroprotective role of adenosine A2A receptor (A2AR) antagonists in PD. Nevertheless, the precise molecular mechanisms underlying this neuroprotection remain unclear. We assessed the impact of A2AR blockade or genetic deletion (A2AR KO) on synaptic plasticity and neuronal cell death induced by aSyn oligomers. We found that impairment of LTP associated with aSyn exposure was rescued in A2AR KO mice or upon A2AR blockade, through an NMDA receptor-dependent mechanism. The mechanisms underlying these effects were evaluated in SH-SY5Y cells overexpressing aSyn and rat primary neuronal cultures exposed to aSyn. Cell death in both conditions was prevented by selective A2AR antagonists. Interestingly, blockade of these receptors did not interfere with aSyn oligomerization but, instead, reduced the percentage of cells displaying aSyn inclusions. Altogether, our data raise the possibility that the well-documented effects of A2AR antagonists involve the control of the latter stages of aSyn aggregation, thereby preventing the associated neurotoxicity. These findings suggest that A2AR represent an important target for the development of effective drugs for the treatment of PD and related synucleinopathies.

Citing Articles

The Role of Purine Metabolism and Uric Acid in Postnatal Neurologic Development.

Mileti L, Baleja J Molecules. 2025; 30(4).

PMID: 40005150 PMC: 11858483. DOI: 10.3390/molecules30040839.


Membrane Heteroreceptor Complexes as Second-Order Protein Modulators: A Novel Integrative Mechanism through Allosteric Receptor-Receptor Interactions.

Mirchandani-Duque M, Choucri M, Hernandez-Mondragon J, Crespo-Ramirez M, Perez-Olives C, Ferraro L Membranes (Basel). 2024; 14(5).

PMID: 38786931 PMC: 11122807. DOI: 10.3390/membranes14050096.


Adenosine A Receptor Blockade Provides More Effective Benefits at the Onset Rather than after Overt Neurodegeneration in a Rat Model of Parkinson's Disease.

Nunes A, Carmo M, Behrenswerth A, Canas P, Agostinho P, Cunha R Int J Mol Sci. 2024; 25(9).

PMID: 38732120 PMC: 11084368. DOI: 10.3390/ijms25094903.


A crazy trio in Parkinson's disease: metabolism alteration, α-synuclein aggregation, and oxidative stress.

Li S, Liu Y, Lu S, Xu J, Liu X, Yang D Mol Cell Biochem. 2024; 480(1):139-157.

PMID: 38625515 DOI: 10.1007/s11010-024-04985-3.


Genetic modifiers of synucleinopathies-lessons from experimental models.

Lee R, Koh T Oxf Open Neurosci. 2024; 2:kvad001.

PMID: 38596238 PMC: 10913850. DOI: 10.1093/oons/kvad001.